Clinical Trials Logo

Adult Acute Myeloid Leukemia clinical trials

View clinical trials related to Adult Acute Myeloid Leukemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01807091 Completed - Clinical trials for Adult Acute Myeloid Leukemia

Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Start date: May 21, 2013
Phase: N/A
Study type: Interventional

This pilot clinical trial studies the feasibility of having induction chemotherapy in an outpatient setting. Patients with acute leukemia (AML) or advanced myelodysplastic syndrome (MDS), at least 18 years of age will be examined. Treating eligible patients with induction chemotherapy in an outpatient setting may save in healthcare cost and improve a patients' quality of life.

NCT ID: NCT01484015 Completed - Breast Cancer Clinical Trials

Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia

Start date: February 2011
Phase: Phase 1
Study type: Interventional

This randomized pilot clinical trial studies how well giving prolonged infusion compared to standard infusion of cefepime hydrochloride works in treating patients with febrile neutropenia. Giving cefepime hydrochloride over a longer period of time may be more effective than giving cefepime hydrochloride over the standard time.

NCT ID: NCT01295710 Completed - Clinical trials for Myelodysplastic Syndrome

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

Start date: October 10, 2011
Phase: Phase 3
Study type: Interventional

The study objective is to compare the efficacy and safety of US-ATG-F as a supplement to standard of care prophylaxis versus standard of care prophylaxis alone in moderate to severe chronic GVHD-free survival.

NCT ID: NCT01251575 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Start date: December 1, 2010
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well sirolimus, cyclosporine and mycophenolate mofetil works in preventing graft-vs-host disease (GVHD) in patients with blood cancer undergoing donor peripheral blood stem cell (PBSC) transplant. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving total-body irradiation together with sirolimus, cyclosporine, and mycophenolate mofetil before and after transplant may stop this from happening.

NCT ID: NCT01146223 Completed - Clinical trials for Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)

Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia

Start date: September 2009
Phase: N/A
Study type: Observational

This research study is studying biomarkers in patients with acute promyelocytic leukemia. Studying samples of bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and about biomarkers related to cancer.

NCT ID: NCT01041443 Completed - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Start date: December 2009
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of 5-Fluoro-2'-deoxycytidine (FdCyd) when given together with tetrahydrouridine (THU) in treating patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). FdCyd may inhibit cancer cell growth by increasing the production in cells of compounds that suppress growth or by otherwise killing cells. Although FdCyd is stable as a drug solution, it is rapidly inactivated by an enzyme present in people. THU is included in the treatment to inhibit the enzyme, prolonging the time FdCyd remains in the body